Acceptability of the vaccine against human papilloma virus in adults
DOI:
https://doi.org/10.55204/trc.v3i1.e123Keywords:
Health Care, Recombinant Vaccine Quadrivalent, Human PapillomavirusAbstract
Human papillomavirus (HPV) is responsible for 80% of cases of cervical cancer (CCU), worldwide it is placed in the fourth place of the most common cancers, this disease is preventable through the application of the vaccine, however, this vaccine has low acceptance compared to other vaccines (tetanus, diphtheria, etc). The vaccine is applied to girls who range the ages of 9 and 12, in two doses with an interval of 6 months between each dose, for this reason parents are the ones who play a very important role in accepting the vaccine. According to the results of several researches, the acceptability of the vaccine is good, nevertheless, there may be numerous barriers that prevent vaccination, such as: lack of knowledge about human papilloma virus and the vaccine, the male gender, since they consider that they are not at risk, myths about the adverse effects of the vaccine and in certain regions the cost of the vaccine all lead to reduced acceptability of human papillomavirus vaccine. In this way, it is believed that in order to give a higher acceptability of the vaccine, it is necessary to educate the general population since it will help in decision-making and in this way, higher vaccination rates would be ensured.
Keywords: Patient Acceptance of Health Care, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18.
Downloads
References
Scott-Wittenborn N, Fakhry C. Epidemiology of HPV Related Malignancies. Semin Radiat Oncol. 2021;31(4):286-96. doi:10.1016/j.semradonc.2021.04.001
Guijarro S, Naranjo J, Padilla M, Gutiérez R, Lammers C, Blum RW. Family risk factors associated with adolescent pregnancy: study of a group of adolescent girls and their families in Ecuador. J Adolesc Health. 1999;25(2):166-72. doi:10.1016/s1054-139x(99)00020-8
Organización Mundial de la Salud. Cáncer cervicouterino. OMS. 2022. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/cervical-cancer
Organización Panamericana de la Salud. El VPH es la causa de cáncer cervical, el cuarto cáncer más frecuente entre las mujeres. OPS. 2018. Disponible en: https://www3.paho.org/hq/index.php?option=com_content&view=article&id=14718:about-hpv-vaccine&Itemid=72405&lang=es#gsc.tab=0
Domínguez S., Trujillo T, Aguilar K, Hernández M. Infection with human papillomavirus in adolescents and young adults. Rev Cubana Obstet Ginecol vol.44 no.1 Ciudad de la Habana. 2018. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138-600X2018000100017&lng=es.
Graham SV. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci (Lond). 2017;131(17):2201-2221. doi:10.1042/CS20160786
Okunade KS. Human papillomavirus and cervical cancer [published correction appears in J Obstet Gynaecol. 2020 May;40(4):590]. J Obstet Gynaecol. 2020;40(5):602-608. doi:10.1080/01443615.2019.1634030
Temesgen MM, Alemu T, Shiferaw B, Legesse S, Zeru T, Haile M, et al. (2021) Prevalencia de la infección por el virus del papiloma humano oncogénico (VPH 16/18), lesiones cervicales y sus factores asociados entre mujeres de 21 a 49 años en la región de Amhara, en el norte de Etiopía. PLoS ONE 16(3): e0248949. https://doi.org/10.1371/journal.pone.0248949
Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using real-time polymerase chain reaction analysis. Cancer. 2002;94(8):2199-2210. doi:10.1002/cncr.10439
Graterol S Ivis J, Finol Hector J, Correnti Maria. Virus del papiloma humano en lesiones intraepiteliales escamosas (LIE) de cuello uterino: Tipificación y ultraestructura. Rev. Soc. Ven. Microbiol. 2006; 26( 2 ): 89-94. Disponible en: http://ve.scielo.org/scielo.php?script=sci_arttext&pid=S1315-25562006000200005&lng=es.
Magalhães GM, Vieira ÉC, Garcia LC, De Carvalho-Leite MLR, Guedes ACM, Araújo MG. Update on human papilloma virus - part I: epidemiology, pathogenesis, and clinical spectrum. An Bras Dermatol. 2021;96(1):1-16. doi:10.1016/j.abd.2020.11.003
Abeck D, Tetsch L, Lüftl M, Biedermann T. Extragenital cutaneous warts - clinical presentation, diagnosis and treatment. J Dtsch Dermatol Ges. 2019;17(6):613-634. doi:10.1111/ddg.13878
Tschandl P, Rosendahl C, Kittler H. Cutaneous human papillomavirus infection: manifestations and diagnosis. Curr Probl Dermatol. 2014;45:92-97. doi:10.1159/000355966
Mattoo A, Bhatia M. Verruca vulgaris of the buccal mucosa: A case report. J Cancer Res Ther. 2018;14(2):454-456. doi:10.4103/jcrt.JCRT_47_17
Pennycook KB, McCready TA. Condyloma Acuminata. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK547667/
Allegue F, Fachal C, González-Vilas D, Zulaica A. Papulosis bowenoide lineal. Actas Dermosifiliogr. 2020;111(1):76–7. DOI: 10.1016/j.ad.2018.05.019
Derkay CS. Recurrent respiratory papillomatosis. Laryngoscope. 2001;111(1):57-69. doi:10.1097/00005537-200101000-00011
Bychkovsky BL, Ferreyra ME, Strasser-Weippl K, et al. Control del cáncer cervicouterino en América Latina: Un llamado a la acción. cáncer _ 2016;122(4):502-514. doi:10.1002/cncr.29813
Vandeweyer E, Sales F, Deraemaecker R. Carcinoma verrugoso cutáneo. Br J Plast Surg . 2001;54(2):168-170. doi:10.1054/bjps.2000.344
Kadouri Y, Nouini Y. La tumeur de Buschke-Löwenstein [Buschke-Löwenstein´ tumor]. Pan Afr Med J. 2020;36:359. doi:10.11604/pamj.2020.36.359.13292
Schilling A. Preguntas frecuentes respecto a la vacuna contra el virus papiloma humano [Frequently asked questions regarding the human papillomavirus vaccines]. Revista chilena de infectologia: organo oficial de la Sociedad Chilena de Infectologia, 2018;35(5), 581–586. http://dx.doi.org/10.4067/s0716-10182018000500581.
Organización Panamericana de la salud. Vacuna contra el Virus del Papiloma Humano (VPH). OPS. 2020. Disponible en: https://www.paho.org/es/vacuna-contra-virus-papiloma-humano-vph
González JV, Deluca GD, Correa RM, et al. Strong reduction in prevalence of HPV16/18 and closely related HPV types in sexually active adolescent women following the introduction of HPV vaccination in Argentina. Papillomavirus Res. 2020;10:100208. doi:10.1016/j.pvr.2020.100208
Bergman H, Buckley BS, Villanueva G, Petkovic J, Garritty C, Lutje V, Riveros-Balta A, Low N, Henschke N. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males. Cochrane Database of Systematic Reviews 2019, Issue 11. Art. No.: CD013479. DOI: 10.1002/14651858.CD013479
World Health Organization. Human Papillomavirus Vaccine. Weekly epidemiological record. WHO. 2022, 645–672. Disponible en: https://www.who.int/publications/journals/weekly-epidemiological-record
Allen-Leigh B, Rivera L, Yunes E, Portillo A, Brown B, León L, Vargas G, Salmerón J, Lazcano E. Uptake of the HPV vaccine among people with and without HIV, cisgender and transgender women and men who have sex with men and with women at two sexual health clinics in Mexico City. Hum Vacuna Inmunotro. 2020; 16(4): 981–990. doi:10.1080/21645515.2019.1675456
Oostdijk C, Van Zoonen K, Ruijs WLM, Mollema L. Household decision-making for the MenACWY vaccination: How parents and adolescents deal with an adolescent vaccination decision. Vaccine. 2021;39(31):4283-90. doi:10.1016/j.vaccine.2021.06.036
Walker KK, Owens H, Zimet G. “We fear the unknown”: Emergence, route and transfer of hesitancy and misinformation among HPV vaccine accepting mothers. Prev Med Rep. 2020;20:101240. doi:10.1016/j.pmedr.2020.101240
Ghebre R, Berry-Lawhorn JM, D’Souza G. State of the Science: Screening, Surveillance, and Epidemiology of HPV-Related Malignancies. Am Soc Clin Oncol Educ Book. 2021;41(41):377–88. doi:10.1200/EDBK_325319
Schilling A. Preguntas frecuentes respecto a la vacuna contra el virus papiloma humano [Frequently asked questions regarding the human papillomavirus vaccines]. Revista chilena de infectologia: organo oficial de la Sociedad Chilena de Infectologia, 2018;35(5), 581–586. http://dx.doi.org/10.4067/s0716-10182018000500581.
Guzman-Holst A, DeAntonio R, Prado-Cohrs D, Juliao P. Barriers to vaccination in Latin America: A systematic literature review. Vaccine. 2020;38(3):470-81. doi:10.1016/j.vaccine.2019.10.088
Muthukrishnan M, Loux T, Shacham E, Tiro JA, Arnold LD. Barriers to human papillomavirus (HPV) vaccination among young adults, aged 18–35. Prev Med Rep. 2022;29:101942. doi:10.1016/j.pmedr.2022.101942
Benavides M, Salazar L. Razones que pueden explicar la reducción en la cobertura de vacunación contra VPH en Colombia. Rev CES Salud Pública. 2017; 8 (1): 82-93. Disponible en: https://revistas.ces.edu.co/index.php/ces_salud_publica/article/view/4423
Navarro P, Aznar J, Díez – Domingo J. Ethical considerations of universal vaccination against human papilloma virus. BMC Med Ethics. 2014; 15: 29. doi:10.1186/1472-6939-15-29
Szilagyi PG, Albertin CS, Gurfinkel D, Saville AW, Vangala S, Rice JD, et al. Prevalence and characteristics of HPV vaccine hesitancy among parents of adolescents across the US. Vaccine. 2020;38(38):6027–37. doi:10.1016/j.vaccine.2020.06.074
Zhu S, Chang J, Hayat K, Li P, Ji W, Fang Y. Parental preferences for HPV vaccination in junior middle school girls in China: A discrete choice experiment. Vaccine. 2020;38(52):8310–7. doi:10.1016/j.vaccine.2020.11.020
Palencia-Sánchez F, Echeverry-Coral SJ. Social considerations affecting acceptance of HPV vaccination in Colombia. A systematic review. Rev Colomb Obstet Ginecol. 2020;71(2):178–94. doi:10.18597/rcog.3448
Liddon N, Hood J, Wynn BA, Markowitz LE. Acceptability of human papillomavirus vaccine for males: a review of the literature. J Adolesc Health. 2010;46(2):113-123. doi:10.1016/j.jadohealth.2009.11.199
Belani HK, Sekar P, Guhaniyogi R, Abraham A, Bohjanen PR, Bohjanen K. Human papillomavirus vaccine acceptance among young men in Bangalore, India. Int J Dermatol. 2014;53(11):e486-e491. doi:10.1111/ijd.12401
Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health. 2007;40(2):108-115. doi:10.1016/j.jadohealth.2006.10.007
Grabiel M, Reutzel TJ, Wang S, et al. HPV and HPV vaccines: the knowledge levels, opinions, and behavior of parents. J Community Health. 2013;38(6):1015-1021. doi:10.1007/s10900-013-9725-6
Moore GR, Crosby RA, Young A, Charnigo R. Low rates of free human papillomavirus vaccine uptake among young women. Sex Health. 2010;7(3):287-290. doi:10.1071/SH09136
Vanderpool RC, Casey BR, Crosby RA. HPV-related risk perceptions and HPV vaccine uptake among a sample of young rural women. J Community Health. 2011;36(6):903-909. doi:10.1007/s10900-010-9345-3.
DiAngi YT, Panozzo CA, Ramogola-Masire D, Steenhoff AP, Brewer NT. A cross-sectional study of HPV vaccine acceptability in Gaborone, Botswana. PLoS One. 2011;6(10):e25481. doi:10.1371/journal.pone.0025481
Lau JT, Wang Z, Kim JH, Lau M, Lai CH, Mo PK. Acceptability of HPV vaccines and associations with perceptions related to HPV and HPV vaccines among men who have sex with men in Hong Kong. PLoS One. 2013;8(2):e57204. doi:10.1371/journal.pone.0057204
Blumenthal J, Heyman KP, Trocola RM, Slomovitz BM. Barriers to acceptance of the human papillomavirus prophylactic vaccine. J Pediatr Infect Dis. 2008;3(3):159–65. DOI: 10.1055/s-0035-1556993
Bednarczyk RA. Addressing HPV vaccine myths: practical information for healthcare providers. Hum Vaccin Immunother. 2019;15(7–8):1628–38. doi:10.1080/21645515.2019.1565267
Gomes JM, Silva BM, Santos EFS, et al. Human Papillomavirus (HPV) and the quadrivalent HPV Vaccine among Brazilian adolescents and parents: Factors associated with and divergences in knowledge and acceptance. PLoS One. 2020;15(11):e0241674. doi:10.1371/journal.pone.0241674
Finch L, Huang M, Jeudin P. Knowledge, Acceptance and Uptake of HPV Vaccine Among OB/ GYN Patients (447). Gynecologic Oncology. Volume 166, supplement 1, 2022. doi:10.1016/s0090-8258(22)01669-9
Ahmed D, VanderEnde K, Bhatnagar P, Roy S, Haldar P, Loharikard A. Human papillomavirus (HVP) vaccine introduction in Skkim state: Best practices from de first statewide multiple-age cohort HPV vaccine introduction in India 2018 – 2019. Vaccine. Volume 40, Supplement 1, 31 March 2022, Pages A17-A25. doi:10.1016/j.vaccine.2021.07.02
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Joseline Andrea Clavijo Naula, Juan Carlos Benalcazar, Julio Cesar Ojeda, Jose Ricardo Charry
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the moral and patrimonial rights of their works. They only give to the magazine Tesla Revista Científica the right to the first publication of this. Since Tesla Revista Científica is an open access publication, readers can fully or partially reproduce its content as long as they properly credit the corresponding authors and the journal itself. Tesla Revista Científica undertakes not to make commercial use of the texts it receives and/or publishes.
Our journal is governed by the international policies SHERPA/RoMEO: Green journal: They allow the self-archiving of both the pre-print (draft of a paper) and the post-print (the version corrected and reviewed by peers) and even the final version ( layout as it will be published in the journal).
See also "Copyright and licences".
